Price movement over the last 24 hours
Alcon AG vs SYSCO Corporation — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while SYSCO Corporation trades at $83.08 (market cap $40.46B). The key difference: SYSCO Corporation is the larger of the two by market cap, and SYSCO Corporation pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| ALC | SYY | |
|---|---|---|
Market Cap | $32.69B | $40.46B |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $91.16 |
52-Week Low | $62.02 | $69.30 |
Enterprise Value | $36.28B | $53.94B |
Dividend Yield | 0.54% | 2.6% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Sysco (SYY) trades at $84.62, down 0.25% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q1 2026 earnings, missing EPS estimates, but maintains steady revenue growth, reaching $81.37B in 2025. Analyst consensus is a Buy with a $83.67 price target, supported by recent corporate developments including AI awards and World Cup supply chain preparations.
Outlook remains positive due to strong institutional support and strategic initiatives, though risks include margin pressure from rising costs and high debt levels. The stock's valuation metrics like P/E of 23.4 and P/S of 0.49 suggest reasonable pricing, but investors should monitor execution on future earnings and debt management.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →